NUTRITIONAL PRIMARY PREVENTION OF TYPE I DIABETES IN CHILDREN

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 这是一项多国、多中心、双盲、随机对照试验，旨在确定在出生后至少6个月内断奶至酪蛋白水解物配方是否可降低遗传易感儿童1型糖尿病的发病率。 具有增加的风险相关HLA基因型和受影响的一级亲属的新生儿将被随机分配在出生后的前6-8个月接受牛温和配方奶粉（Enfamil）或酪蛋白水解物配方奶粉（Nutramigen）。 母亲的哺乳愿望不会被打断。 将对受试者进行5年（如果资金允许，则为10年）随访，以确定是否存在胰岛细胞自身免疫的免疫学标志物以及是否发生糖尿病和/或葡萄糖耐受不良。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multinational, multicenter, double-blinded, randomized controlled trial to determine whether weaning to a casein hydrolysate formula during at least the first 6 months of life reduces the incidence of type 1 diabetes in genetically susceptible children. Newborn infants, who have an increased risk-associated HLA genotype and an affected first degree relative, will be randomly assigned to receive either a cow's mild-based formula (Enfamil) or a casein hydrolysate formula (Nutramigen) for the first 6-8 months of life. The mother's breast feeding wishes will not be interrupted. Subjects will be followed for 5 years (10 years if funding allows) for the presence of immunologic markers of islet cell autoimmunity and the development of diabetes and/or glucose intolerance.